FB918
INDICATION
Non-Allergic Eosinophilic Asthma
MECHANISM OF ACTION
FB918 is a fully-human antibody specifically targeting interleukin 33 (IL-33). It is discovered and screened from Oneness-owned antibody library and currently under pre-clinical development. FB918 regulates several cytokines signaling that induces asthma by inhibiting the binding of IL-33 to the ST2 receptor. According to literatures, IL-33 plays as a critical mediator in asthma and inflamed lung tissues. It is also a novel target bring promising future treatment as many global pharma companies are exploring its potential in different indications.
CURRENT STATUS
FB918 is under pre-clinical development.
MARKET POTENTIAL
The treatment of non-allergic eosinophilic asthma is still in unmet medical needs. The increase in the number of type 2 innate lymphocytes (ILC2) in such patients will cause the eosinophils to mature and migrate after being stimulated by IL-33 secreted from epithelial cells, leading to disease onset. According to market analysis reports, the market size of asthma was 18 billion USD and expects to reach 26 billion USD in 2027.